Sector News

Lantheus to buy Progenics to chase both cancer imaging diagnostics and drugs

October 3, 2019
Life sciences

Lantheus, makers of diagnostic imaging hardware and nuclear medicine agents, has moved to acquire cancer drugmaker Progenics Pharmaceuticals in an all-stock transaction.

The new company aims to combine Lantheus’ manufacturing and supply chain background with Progenics’ clinical R&D pipeline and its portfolio of FDA-approved products—including Azedra, a treatment approved last year for the rare orphan indications pheochromocytoma and paraganglioma.

Progenics’ other approved products are oral and subcutaneous formulations of Relistor, for opioid-induced constipation in patients with terminal illness, which have been licensed to Bausch Health.

Meanwhile, Lantheus brings along its microbubble franchise of cardiovascular ultrasound contrast agents, as well as radiopharmaceuticals used in cancer diagnostics. The new company will also offer a 510(k)-cleared artificial intelligence platform in oncology.

“With this combination, we broaden our reach in emerging uses of radioisotopes for precision diagnostics and the exciting and expanding field of radiopharmaceuticals in oncology treatment,” Lantheus President and CEO Mary Anne Heino said in a statement, describing a focus in diagnosing and treating neuroendocrine tumors and prostate cancer.

“We have assessed the strategic fit with Progenics for a number of years and I am pleased that we are finally able to make this combination come to fruition; I believe that the combined company will be well-positioned for long-term value creation for all of our stockholders,” said Heino, who will lead the company going forward, headquartered out of Lantheus’ home in North Billerica, Massachusetts.

Under the deal, Lantheus’ holding company will purchase all of Progenics’ issued and outstanding common shares—in exchange for 0.2502 shares of Lantheus stock for each—which will represent about a 35% ownership stake in the combined venture going forward. According to the companies, the two had a pro forma combined revenue of $370.1 million for the 12 months preceding June 30.

Lantheus said the exchange ratio comes to a 21.5% premium over Progenics’ average closing stock price. However, Lantheus’ stock plunged at least 20% following news of the deal to about $18.80. The deal has been approved by the boards of both companies.

“Today marks the beginning of an exciting new chapter for Progenics,” said CEO Mark Baker. “Lantheus shares our confidence in the potential of our promising pipeline, and we believe that Lantheus will provide additional commercialization expertise and resources to further advance Azedra’s launch and deliver substantial revenue growth.”

The transaction is expected to close in the first quarter of 2020, subject to approval by both companies’ stockholders and regulators.

By Conor Hale

Source: Fierce Biotech

comments closed

Related News

July 3, 2022

Novo Nordisk joins with nursing group to highlight correlation between Type 2 diabetes and cardio risk

Life sciences

Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.

July 3, 2022

First treatment for ‘broken heart syndrome’ trialled

Life sciences

The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.

July 3, 2022

Nestlé acquiring The Better Health Company in market expansion deal

Life sciences

Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.